替吉奥对晚期乳腺癌患者血清TK1、VEGF、IGF－1和肿瘤标志物、雌激素水平的影响

摘要

Objective To investigate the effect of S-1 on serum thymidine kinase-1 ( TK1 ) , vascular endothelial growth factor ( VEGF ) and insulin-like growth factor-1 (IGF-1) and tumor biomarkers, estrgen levels and quality of life in patients with advanced breast cancer.Methods 69 cases with advanced breast cancer from January 2014 to May 2015 in the hospital were selected and randomly divided into two groups.34 cases in control group were treated by conventional therapy, and 34 cases in experimental group were treated with S-1.Serum TK1, VEGF and IGF-1, tumor biomarkers, estrogen level and quality of life score were compared pre-and post-treatment.ResuIts Compared with control group, the levels of VEGF, IGF-1 and TK1 were lower (P<0.05), serum CA125, CEA and CA15-3 concentrations were lower (P<0.05),the LH, E2 and E1 levels were lower (P<0.05) and the survival quality score was higher in experimental group ( P<0.05 ) .ConcIusion S-1 has better clinical curative effect in treatment of patients with advanced breast cancer, and effectively reduce serum TK1, VEGF, IGF-1, tumor biomarker levels, improve the quality of survival, which has important significance.%目的：探讨替吉奥对晚期乳腺癌患者血清胸苷激酶1（thymidine kinase－1，TK1）、血管内皮生长因子（vascular endothelial growth factor，VEGF）及胰岛素样生长因子1（insulin－like growth factor－1，IGF－1）、肿瘤标志物、雌激素水平及生存质量的影响。方法选取2014年1月～2015年5月于贵阳医学院附属黔东南州人民医院诊治的晚期乳腺癌患者69例，根据随机数字表法随机分为2组：对照组34例，给予常规治疗；实验组35例，在对照组基础上加用替吉奥治疗，检测并比较2组患者治疗前后血清TK1、VEGF、IGF－1、肿瘤标志物、雌激素水平及生存质量评分。结果治疗后，与对照组比较，实验组血清TK1、VEGF、IGF－1水平较低（P＜0．05），实验组血清癌胚抗原（CEA）、糖类抗原15－3（CA15－3）及糖类抗原125（CA125）浓度水平较低（P＜0．05），实验组血清雌二醇（estradiol，E2）、雌酮（estrone，E1）及黄体生成素（luteinizing hormone，LH）水平水平较低（P＜0．05），实验组生存质量评分较高（P＜0．05）。结论替吉奥对晚期乳腺癌患者治疗据有较好的临床疗效，且能有效降低血清TK1、VEGF、IGF－1和肿瘤标志物水平，从而提高生存质量。